AbbVie Inc. ABBV

264.34 (0.78) (0.29%) as of 25 Sep
Market cap
$467.4B
P/E
74.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

AbbVie Inc. (ABBV) P/S ratio

As of 25 September 2026, AbbVie Inc. (ABBV) trades at a P/S ratio of 7.3×. Over the past ten years it has ranged from 2.9× (August 2019) to 7.3× (August 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 6.6× 18.44%
FY2024 5.6× 7.27%
FY2023 5.2× 5.01%
FY2022 5.0× 16.16%
FY2021 4.3× 9.36%
FY2020 3.9× (1.07%)
FY2019 3.9× (9.12%)
FY2018 4.3× (22.08%)
FY2017 5.6× 40.98%
FY2016 3.9× (6.24%)

Quarterly

Period P/S ratio Change
Jun 2026 6.9× 12.82%
Mar 2026 6.1× (7.28%)
Dec 2025 6.6× (3.76%)
Sep 2025 6.9× 22.05%
42 more quarters

Against its own ten years

Low 2.9× High 7.3×
Ten-year median 4.5×
Current reading's percentile 100

P/S ratio against peers

Company P/S ratio
PFE Pfizer Inc. compare 2.6×
AZN AstraZeneca PLC compare 4.2×
NVS Novartis AG compare 4.9×
MRK Merck & Co., Inc. compare 5.5×
AMGN Amgen Inc. compare 5.9×
GILD Gilead Sciences, Inc. compare 6.2×
JNJ Johnson & Johnson compare 6.7×
ABBV AbbVie Inc. 7.3×
LLY Eli Lilly and Company compare 13.3×
Drug Manufacturers General industry median 3.3×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on ABBV